FT. LAUDERDALE, Fla., Aug. 19, 2015 (GLOBE NEWSWIRE) -- CNS Response, Inc. (OTCQB:CNSO)
CNS Response presented clinical results at the annual Military Health System Research Symposium (MHSRS) in Ft. Lauderdale, FL. The Company briefed senior military leadership on PEER, the largest "big data" registry in mental healthcare, and its impact on trial & error prescribing. Pooled results of three randomized controlled trials, conducted at sites including the Veterans Administration, Harvard, Stanford, UCI, University of Texas, and Rush Presbyterian Hospital were presented, with the following key findings:
-
Medication effectiveness doubled for physicians using PEER instead of trial and error prescribing, with a 43% average improvement when using PEER vs. 20% for the non-PEER group. Results were consistent and statistically significant across all studies.
-
Half the time to get to the right treatment. The PEER group also saw improvement 25-50% faster, meaning patients needed fewer visits for physicians to get to the right medication. This improvement in treatment efficiency could directly impact waiting lists, staffing, budgets, and patient adherence to treatment.
- Overall predictive accuracy for PEER is 86%, which is better than mammography (61%), EKG (65%), and many of the most commonly used tests.
In addition, medication risks were reviewed from an observational study of 435 commercial health plan members:
-
85% reduction in patient suicidality when PEER was used.
- Patients receiving medications contraindicated by PEER were twice as likely to have severe adverse events in two trials.
"These are powerful results, and because they were achieved with tools we have today, they could make a huge difference in patient care — today" said George Carpenter, CEO of CNS Response. "We have been working with the military for 5 years, in an area of medicine that needs 'emergency science'. This year Secretary Carter challenged the DoD to do a better job embracing tech companies that drive rapid innovation. These results underscore the urgency of funding and expanding this technology within the DoD and VA."
To review the data, click here to view on the web: MHSRS 2015 - PEER Summary
About CNS Response Inc.
CNS Response (www.cnsresponse.com) provides a unique set of reference data and analytic tools for clinicians and researchers in psychiatry. While treatment for mental disorders has doubled in the last 20 years, it is estimated that 17 million Americans have failed two or more medication therapies for their mental disorders. The Company's Psychiatric EEG Evaluation Registry, or PEER Online, is a new registry and reporting platform that allows medical professionals to exchange treatment outcome data for patients referenced to objective neurophysiology data obtained through a standard electroencephalogram (EEG). Based on the company's original physician-developed database, there are now more than 38,000 outcomes for over 10,000 unique patients in the PEER registry. The objective of PEER Online is to reduce trial and error pharmacotherapy, which is the dominant approach for treatment resistant patients.
To read more about the benefits of this patented technology for patients, physicians and payers, please visit www.cnsresponse.com. Medical professionals interested in learning more about PEER can contact CNS Response representatives at PEERinfo@cnsresponse.com.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements involve risks and uncertainties as set forth in the Company's filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.